Drug Sales Trends for COMPRO

Payment Methods and Pharmacy Types for COMPRO (2003)

Revenues by Pharmacy Type

Pharmacy Type	Revenues
INSIDE HMO/CLINIC/HOSPITAL	$219,461
DRUG STORE	$115,831

Units Sold by Pharmacy Type

Pharmacy Type	Units
INSIDE HMO/CLINIC/HOSPITAL	5,283
DRUG STORE	6,778

Revenues by Payment Method

Payment Method	Revenues
PRIVATE INSURANCE	$7,374
SELF OR FAMILY	$327,917

Select year for charts:

[2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 ]

Annual Sales Revenues and Units Sold for COMPRO

These sales figures are drawn from a US national survey of drug expenditures

Drug Name	Revenues (USD)	Units	Year
COMPRO			2022
COMPRO			2021
COMPRO			2020
COMPRO			2019
COMPRO			2018
COMPRO			2017

COMPRO Market Analysis, Sales Forecast, Patent Position, and Generic Risk

Last updated: September 17, 2026

COMPRO is a U.S. prescription rectal suppository containing prochlorperazine, generally supplied as a 25 mg dosage form for severe nausea and vomiting. Its commercial market is small, mature, and largely genericized. Public filings do not disclose standalone COMPRO revenue, unit volume, or net pricing. A reasonable U.S. net-sales estimate is approximately $5 million to $12 million annually, with a base-case forecast of roughly $9 million by 2029 under stable supply and limited price erosion.

What is COMPRO and what market does it serve?

COMPRO is a rectal formulation of prochlorperazine, a phenothiazine antiemetic and dopamine antagonist. The product is used primarily when oral administration is impractical because of vomiting, impaired consciousness, or acute gastrointestinal illness.

Attribute	COMPRO profile
Active ingredient	Prochlorperazine
Dosage form	Rectal suppository
Common strength	25 mg
Route	Rectal
Therapeutic class	Antiemetic; phenothiazine
Primary use	Severe nausea and vomiting
U.S. regulatory pathway	Prescription drug
Market structure	Mature, low-volume generic market
Principal alternatives	Prochlorperazine tablets and injection, promethazine suppositories, ondansetron, metoclopramide
Commercial position	Niche dosage form with limited direct competition

The rectal route gives COMPRO a specific clinical role, but the same characteristic limits its addressable market. Most patients with nausea can receive oral, orally disintegrating, injectable, or intravenous therapy. Rectal delivery is most useful in acute-care situations where oral treatment is unsuitable.

The FDA-approved labeling identifies prochlorperazine suppositories for control of severe nausea and vomiting in adults. The product carries phenothiazine-class safety restrictions, including risks associated with extrapyramidal reactions, tardive dyskinesia, neuroleptic malignant syndrome, hypotension, and sedation (DailyMed, n.d.).

What is the current market size for COMPRO?

No public source reports COMPRO as a separate revenue line. The product is not a major contributor to the global antiemetic market, and standard market-research reports generally group it with prochlorperazine or broader antiemetic categories.

A bottom-up estimate places annual U.S. net sales in the following range:

Scenario	Estimated annual U.S. net sales	Commercial interpretation
Low	$2 million-$5 million	Limited availability, weak reimbursement, substitution by other antiemetics
Base	$5 million-$12 million	Stable hospital and outpatient demand
High	$12 million-$20 million	Supply continuity, price realization, and limited alternatives

These figures are modeled estimates rather than reported sales. The market is likely driven by institutional purchasing, wholesalers, emergency departments, hospital formularies, and a small outpatient segment.

The product’s value is concentrated in availability. A suppository can retain demand even when its clinical volume is low because hospitals and pharmacies may maintain it as an alternative dosage form for patients who cannot tolerate oral medication.

What are the COMPRO sales projections through 2029?

The base case assumes stable U.S. availability, no major label expansion, moderate pricing pressure, and continued substitution by lower-cost or more convenient antiemetic products.

Fiscal year	Low case	Base case	High case
2025E	$3.0 million	$7.0 million	$12.0 million
2026E	$2.8 million	$7.4 million	$12.6 million
2027E	$2.7 million	$7.8 million	$13.2 million
2028E	$2.6 million	$8.3 million	$13.9 million
2029E	$2.5 million	$8.8 million	$14.6 million
Implied CAGR	-4.5%	5.9%	5.0%

The base case reflects a small increase in nominal sales from price adjustments and stable demand, not meaningful volume growth. Real unit demand is likely flat or declining.

What assumptions drive the forecast?

The projection uses five commercial assumptions:

1. COMPRO remains available in the U.S. throughout the forecast period.
2. The product retains a limited institutional and outpatient customer base.
3. Average net pricing rises by approximately 2% to 4% annually.
4. Unit volume declines slightly as ondansetron, promethazine, and injectable products capture treatment demand.
5. No new competitor materially disrupts the rectal prochlorperazine market.

A supply interruption would have a disproportionate effect because the market is small and pharmacy inventories may be limited. Conversely, a shortage of competing antiemetics could produce temporary revenue spikes without changing the long-term market position.

What is the competitive landscape for COMPRO?

COMPRO competes against products that are usually more convenient, more familiar to prescribers, or easier to administer.

Competitor	Dosage forms	Competitive advantage over COMPRO
Generic prochlorperazine	Tablet, oral solution, injection	Same active ingredient and broader administration options
Promethazine	Tablet, liquid, suppository, injection	Established antiemetic use and direct rectal alternative
Ondansetron	Tablet, ODT, oral solution, injection	Broad use, favorable tolerability, convenient ODT form
Metoclopramide	Tablet, liquid, injection	Established use in nausea and gastrointestinal motility disorders
Dimenhydrinate and related agents	Oral and injectable forms	Over-the-counter or low-cost access in some settings

Ondansetron is the principal commercial substitute in many acute-care settings, although it does not provide a rectal dosage form. Promethazine suppositories are the closest direct route competitor. Prochlorperazine tablets and injection also reduce the need for COMPRO when those routes are clinically acceptable.

The product’s defensibility is therefore based on dosage-form availability and clinical utility, not on a differentiated molecule or broad therapeutic superiority.

What is the FDA regulatory status of COMPRO?

COMPRO is an FDA-regulated prescription product. Prochlorperazine is an established active ingredient with decades of clinical use. The product does not appear to depend on a recent New Drug Application exclusivity period or a novel active-ingredient protection strategy.

The regulatory risks are operational rather than developmental:

• Maintaining an approved manufacturing process.
• Meeting current good manufacturing practice requirements.
• Preserving supply of suppository materials and packaging.
• Maintaining stability data and quality controls.
• Managing labeling requirements for phenothiazine-related safety risks.
• Avoiding manufacturing interruptions that could trigger product unavailability.

The FDA Orange Book should be reviewed for the current reference-listed-drug designation, therapeutic-equivalence listings, and any active patent or exclusivity entries. For an old prochlorperazine suppository, the practical expectation is that market protection is limited and that any commercial advantage comes from supply reliability, customer contracts, and manufacturing capability rather than regulatory exclusivity (FDA, n.d.-a).

What patents protect COMPRO and when does exclusivity expire?

The original composition-of-matter protection for prochlorperazine has long expired. No commercially meaningful active-ingredient exclusivity should be assumed for COMPRO.

Potential intellectual-property categories include:

• Historical patents covering prochlorperazine or its salts.
• Formulation patents covering suppository excipients or manufacturing processes.
• Manufacturing know-how involving molding, uniformity, stability, and packaging.
• Trademark rights in the COMPRO brand.
• Regulatory records associated with the approved product.

The remaining commercial protection is likely weak relative to a new chemical entity. A formulation patent could create a narrower barrier, but a competitor could potentially design around it by using different excipients, manufacturing conditions, or packaging. Brand rights prevent confusingly similar branding but do not block generic prochlorperazine products.

Are there Paragraph IV challenges to COMPRO?

A current, commercially material Paragraph IV challenge is not apparent from the public profile of this mature product. Paragraph IV litigation is more relevant when an active Orange Book patent blocks an abbreviated new drug application. For COMPRO, the more likely competitive path is an ANDA supported by established prochlorperazine labeling and pharmaceutical equivalence requirements.

A generic entrant could still create litigation if an active formulation or process patent were listed. That risk cannot be quantified from product labeling alone. The absence of a prominent, active patent dispute supports the view that the main threats are price competition and substitution rather than patent litigation.

What generic entry risks exist for COMPRO?

Generic entry risk is structurally high because:

• The active ingredient is old and well characterized.
• The dosage form is established.
• Clinical development requirements are limited compared with a new drug.
• Prescribers can substitute among prochlorperazine products.
• FDA approval does not require proving superior clinical efficacy.
• The market has few barriers based on molecule ownership.

However, the market may not attract numerous entrants. Rectal suppositories require specialized manufacturing, relatively small production runs, stability controls, and reliable distribution. Expected revenue may be too low to justify development for some manufacturers.

This creates a tension between legal vulnerability and practical competition. COMPRO may have weak patent protection but retain some commercial value if manufacturing complexity and low market size discourage aggressive entry.

How strong is the COMPRO patent estate?

The patent estate is likely weak by branded-pharmaceutical standards and moderate only in relation to manufacturing execution.

Protection category	Estimated strength	Commercial effect
Active ingredient	Very weak	Historical protection expired
Core indication	Weak	Established antiemetic use is difficult to protect broadly
Rectal dosage form	Low to moderate	Narrow formulation claims may be possible
Manufacturing process	Moderate if proprietary	May increase entry cost but can be designed around
Trademark	Moderate for brand identity	Does not prevent generic substitution
Regulatory exclusivity	Minimal or expired	Does not materially delay entry

The most valuable assets are likely the approved product, manufacturing know-how, customer relationships, and supply history. These assets can support a niche business but do not create a high barrier to substitution.

What commercial factors could increase COMPRO revenue?

Revenue upside would most likely come from execution rather than new clinical indications.

Potential drivers include:

• Winning hospital or group-purchasing contracts.
• Maintaining uninterrupted supply during competitor shortages.
• Expanding pharmacy and long-term-care distribution.
• Improving wholesaler availability.
• Preserving reimbursement in plans that cover rectal antiemetics.
• Developing package sizes suited to institutional use.
• Licensing or acquiring complementary antiemetic products.

A shortage-driven increase could be temporary. It should not be valued as recurring growth unless supply conditions persist and prescribing behavior changes.

What factors could reduce COMPRO revenue?

The principal downside factors are:

• Generic price erosion.
• Discontinuation or intermittent supply.
• Greater use of ondansetron ODT and injectable antiemetics.
• Hospital formulary removal.
• Reimbursement restrictions.
• Manufacturing-cost inflation.
• Safety concerns associated with phenothiazines.
• A competing prochlorperazine suppository with lower pricing.
• Reduced prescribing for older antiemetic agents.

The most severe scenario is not gradual competition but loss of reliable supply. A niche product can lose formulary presence quickly after repeated back orders.

What is the investment and licensing outlook for COMPRO?

COMPRO is more suitable as a portfolio add-on than as a standalone growth asset. Its value would be highest for a company that already has:

• U.S. hospital distribution.
• Suppository manufacturing capacity.
• A mature generic or specialty-pharmaceutical portfolio.
• Established relationships with wholesalers and group-purchasing organizations.
• Additional antiemetic or acute-care products for cross-selling.

A licensing transaction would likely depend on minimum purchase commitments, supply obligations, manufacturing transfer terms, and rights to related prochlorperazine products. A high upfront payment would be difficult to justify without verified sales, stable supply data, and evidence of durable reimbursement.

Key Takeaways

• COMPRO is a mature prochlorperazine 25 mg rectal suppository with a narrow U.S. market.
• Public sources do not disclose standalone COMPRO sales.
• Estimated annual U.S. net sales are approximately $5 million to $12 million, with a modeled base case of $8.8 million in 2029.
• The active ingredient has no meaningful remaining composition-of-matter exclusivity.
• Patent risk is likely lower than supply, reimbursement, and substitution risk.
• Direct competition comes from promethazine suppositories; broader competition comes from ondansetron, prochlorperazine tablets and injection, and metoclopramide.
• The strongest commercial asset is reliable availability in a dosage form used when oral administration is unsuitable.
• COMPRO is more attractive as a niche portfolio product than as a standalone growth platform.

FAQs About COMPRO Market Sales and Exclusivity

Is COMPRO still commercially available in the United States?

COMPRO has been marketed as a prescription prochlorperazine suppository. Current availability can vary by manufacturer, wholesaler inventory, and pharmacy distribution.

Does COMPRO have FDA exclusivity?

No meaningful new-drug exclusivity should be assumed for this mature prochlorperazine product. Any current protection would more likely involve product-specific patents, trademarks, or manufacturing know-how.

Is COMPRO a generic drug?

COMPRO is a branded product containing the established generic active ingredient prochlorperazine. Therapeutically equivalent prochlorperazine products can compete with it, subject to FDA approval and product-specific equivalence requirements.

What is the main reason physicians use COMPRO?

The principal reason is the rectal route, which can be useful when a patient cannot retain oral medication or when oral administration is impractical.

Could COMPRO sales grow materially?

Material growth is unlikely without a supply disruption affecting competing products, a new distribution strategy, or portfolio expansion. The base case is stable to modestly growing nominal revenue with limited unit-volume growth.

References

DailyMed. (n.d.). COMPRO- prochlorperazine suppository. U.S. National Library of Medicine. https://dailymed.nlm.nih.gov/

U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

U.S. Food and Drug Administration. (n.d.-b). Drugs@FDA. https://www.accessdata.fda.gov/scripts/cder/daf/

U.S. Food and Drug Administration. (n.d.-c). Abbreviated new drug application approvals. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/anda-approvals